Mu.Ta.Lig - COST ACTION CA15135


14 June 2016


General information

Name: José
Surname: Marco-Contelles
Cell phone number with international prefix: +34690391554
Country: Spain
Affiliation: Laboratory of Medicinal Chemistry (Institute of General Organic Chemistry, CSIC); 3, Juan de la Cierva; 28006-Madrid (Spain)
Gender: F □ M X
Year of the PhD title: 1984
Personal web page: http://
Previous COST participation: No □ Yes X (COST 1103)


List of 10 selected publications within last 5 years

1. M. I. Ayuso, M. Chioua, E. Martinez-Alonso, E. Soriano, J. Montaner, J. Masjuán, D. Hadjipavlou-Litina, J. Marco-Contelles, A. Alcazar, 2015, Journal of Medicinal Chemistry, 58: 6704-6709.
2. O. M. Bautista-Aguilera, A. Samadi, M. Chioua, K. Nikolic, S. Filipic, D. Agbaba, E. Soriano, L. de Andrés, M. I. Rodríguez-Franco, S. Alcaro, R. Ramsay, F. Ortuso, M. Yañez, and J. Marco-Contelles, 2014, N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamino oxidase dual inhibitor, Journal of Medicinal Chemistry, 57: 10455-10463.
3. M. Chioua, D. Sucunza, E. Soriano, D. Hadjipavlou-Litina, A. Alcázar, I. Ayuso, M. J. Oset-Gasque, M. P. González, L. Monjas, M. I. Rodríguez-Franco, J. Marco-Contelles, and A. Samadi, 2012, a-Aryl-N-alkyl nitrones, as potential agents for stroke treatment: Synthesis, theoretical calculations, antioxidant, anti-inflammatory, neuroprotective and brain-blood barrier permeability properties, Journal of Medicinal Chemistry, 55:153-168.
4. I. Bolea, J. Juárez-Jiménez, C. de los Ríos, M. Chioua, R. Pouplana, F. J. Luque, M. Unzeta, J. Marco-Contelles, and A. Samadi, 2011, Synthesis, biological evaluation and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids, as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease, Journal of Medicinal Chemistry, 54: 8251-8270.
5. S. Lorrio, A. Romero, L. González-Lafuente, R. Lajarín-Cuesta, F. J. Martínez-Sanz, M. Estrada, A. Samadi, J. Marco-Contelles, M. I. Rodríguez-Franco, M. Villarroya, M. G. López, and C. de los Ríos, 2013, PP2A ligand ITH12246 protects against memory impairment and focal cerebral ischemia in mice, ACS Chemical Neuroscience, 4: 1267-1277.
6. D. Silva, M. Chioua, A. Samadi, P. Agostinho, P. Garçao, R. Lajarin-Cuesta, C. de los Rios, I. Iriepa, I. Moraleda, L. Gonzalez-Lafuente, M. E. Mendes, C. Pérez, M. I. Rodríguez-Franco, J. Marco-Contelles, and M. C. Carreiras, 2013, Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: Effect against amyloid-β-induced neurotoxicity, ACS Chemical Neuroscience, 4: 547-565.
7. L. Wang, G. Esteban, M. Ojima, O. M. Bautista-Aguilera, T. Inokuchi,* I. Iriepa, A. Samadi, M. B. H. Youdim, A. Romero, R. Herrero, A. P. Fernández Fernández, R. Martínez-Murillo, J. Marco-Contelles, and M. Unzeta*, 2014, Donepezil+propargylamine+8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer’s disease, European Journal of Medicinal Chemistry, 80: 543 – 561.
8. C. Arce, S. Diaz-Castroverde, M. J. Canales, J. Marco-Contelles, A. Samadi, M. J. Oset-Gasque, and M. P. González, 2012, Drugs for stroke: Action of nitrone (Z)-N-(2-bromo-5-hydroxy-4-methoxybenzylidene)-2-methylpropan-2-amine oxide on rat cortical neurons in culture subjected to oxygen-glucose-deprivation, European Journal of Medicinal Chemistry, 55: 475-479
9. C. Martins, M. C. Carreiras, R. León,  C. de los Ríos, M. Bartolini, V. Andrisano, I. Iriepa, I. Moraleda, E. Gálvez, M. G. López, J. Egea, A. Samadi, M. Chioua, and J. Marco-Contelles, 2011, Synthesis and biological assessment of diversely substituted furo[2,3-b]quinolin-4-amine and pyrrolo[2,3-b]quinolin-4-amine derivatives, as novel tacrine analogues, European Journal of Medicinal   Chemistry, 46: 6119-6130
10. R. León, A. G. García, and J. Marco-Contelles, 2013, Recent advances in the multi-target directed ligands approach for the treatment of Alzheimer’s disease, Medicinal Research Reviews, 33: 139-189.


Main skills and expertise (up to 5)

1. Design and organic synthesis
2. New agents for Alzheimer’s disease and stroke
3. Heterocycles
4. Polypharmacology
5. Catalysis: Transition-metal promeoted cyloisomerization reactions


Main equipment/facilities available in the participants’ lab (up to 5)

1. IR, UV
2. NMR
3. Mass spectrometry
4. Elemental analysis
5. glc, HPLC, CD, polarimeter


Short personal activity proposal for the COST Action CA15135 (max 1000 characters)

For the present COST Action, we propose the design, synthesis and biological evaluation of new multitarget and polyvalent molecules for  the treatment of diseases of ageing, such as Alzheimer’s disease (AD) and stroke. The new molecules are nitrones designed as inhibitors of monoamine oxidases, and cholinesterases, showing strong chelating and antioxidant properties. The target compounds result from the juxtaposition of ASS234 and RP19, two compounds previously developed in our laboratory for AD and stroke therapy, respectively. ASS234 is a neuroprotective and dual inhibitor of MAOs and ChEs, showing significant capacity to prevent the beta-amyloid aggregation in the cortex of double-transgenic mice. RP19 is an antioxidant quinolylnitrone tested with success in a global and focal cerebral ischemia. Based on the in vitro biological evaluation, we will be able to identify several hit molecules, ready for the in vivo studies. Finally, we expect to identify a lead-compound for the pre-clinical studies.


Work Group preference: score from 1 (preferred) to 4 (not preferred)

Work Group of the CA15135 COST Action Score
WG1: Development of new chemical entities 1
WG2: Selection of biological targets and assessment of biological data 2
WG3: Development of chemical databases 4
WG4: Development of Computational methods for multiple ligand design and discovery 4